Long-term follow-up of Crohn disease fistulas after local injections of bone marrow-derived mesenchymal stem cells

Rachele Ciccocioppo, Alessandra Gallia, Adele Sgarella, Peter Kruzliak, Paolo G. Gobbi, Gino Roberto Corazza

Research output: Contribution to journalArticlepeer-review

Abstract

Objective To assess the long-term outcome of patients treated with serial intrafistular injections of autologous bone marrow-derived mesenchymal stem cells (MSCs) for refractory Crohn fistulas in terms of safety and efficacy. Patients and Methods Starting from January 10, 2007, through June 30, 2014, clinical evaluation, calculation of the Crohn disease activity index (CDAI), therapeutic management, and documentation of adverse events in 8 of the 10 patients (5 men; median age, 37 years) who had been injected locally with MSCs were prospectively recorded for 72 months. Cumulative probabilities of fistula recurrence and medical or surgical treatment were estimated using a Kaplan-Meier method, whereas differences among the pre- and post-MSC CDAI values were calculated with the Mann-Whitney U test. Results Following disease remission observed after 12 months from MSC treatment (P

Original languageEnglish
Pages (from-to)747-755
Number of pages9
JournalMayo Clinic Proceedings
Volume90
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Long-term follow-up of Crohn disease fistulas after local injections of bone marrow-derived mesenchymal stem cells'. Together they form a unique fingerprint.

Cite this